Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS410 in uncomplicated influenza A
NCT02989194Phase 2Completed
- Sponsor
- Visterra
- Start
- Jan 2017
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of VIS410 in Influenza A infection (3 arms), sponsored by Visterra. Primary endpoints: Assess the Safety and Tolerability of a Single IV Dose of VIS410 in Participants With Uncomplicated Influenza Infection at 100 days and Percentage of Participants With Any Treatment-emergent Adverse Event (TEAE) and TEAEs of Special Interest at 100 days. Started Jan 2017; status: completed.
02
Drugs
VIS410
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on NCT02989194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989194.